Acrocomia aculeata associated with doxorubicin: cardioprotection and anticancer activity
Authors:
Open Access
- 16 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1223933
Abstract
Doxorubicin (Dox) is a chemotherapeutic agent widely used in the clinic, whose side effects include cardiotoxicity, associated with decreased antioxidant defenses and increased oxidative stress. The association of Dox with natural antioxidants can extend its use if not interfering with its pharmacological potential. In this study, we aimed to understand the effects and mechanisms of the aqueous extract of Acrocomia aculeata leaves (EA-Aa) in cancer cells and the co-treatment with Dox, in in vitro and in vivo models. It was found that EA-Aa showed a relevant decrease in the viability of cancer cells (K562 and MCF-7) and increased apoptosis and death. The Dox cytotoxic effect in co-treatment with EA-Aa was increased in cancer cells. The therapeutic association also promoted a change in cell death, leading to a higher rate of apoptosis compared to the Dox group, which induced necrosis. In addition, in non-cancer cells, EA-Aa enhanced red blood cell (RBC) redox state with lower hemolysis and malondialdehyde (MDA) content and had no in vitro nor in vivo toxicity. Furthermore, EA-Aa showed antioxidant protection against Dox-induced cytotoxicity in H9c2 cells (cardiomyoblast), partially mediated by the NRF2 pathway. In vivo, EA-Aa treatment showed a relevant decrease in MDA levels in the heart, kidney, and brain, evaluated in C57Bl/6 mice induced to cardiotoxicity by Dox. Together, our results proved the effectiveness of EA-Aa in potentiating Dox anticancer effects, with antioxidant and cardioprotective activity, suggesting EA-Aa as a potential Dox pharmacological adjuvant.Keywords
This publication has 48 references indexed in Scilit:
- Antioxidant and Cytotoxic Activity of Hydroethanolic Extract from Jacaranda decurrens LeavesPLOS ONE, 2014
- Natural compounds to overcome cancer chemoresistance: toxicological and clinical issuesExpert Opinion on Drug Metabolism & Toxicology, 2014
- Nrf2 Deficiency Exaggerates Doxorubicin-Induced Cardiotoxicity and Cardiac DysfunctionOxidative Medicine and Cellular Longevity, 2014
- Doxorubicin-antioxidant co-drugsBioorganic & Medicinal Chemistry Letters, 2013
- Chemistry and Biological Activities of Flavonoids: An OverviewThe Scientific World Journal, 2013
- Cardiac side-effects of cancer chemotherapyInternational Journal of Cardiology, 2010
- Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymesFood and Chemical Toxicology, 2008
- Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsBritish Journal of Pharmacology, 2007
- Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well?British Journal of Pharmacology, 2006
- Screening of Antioxidants from Medicinal Plants for Cardioprotective Effect against Doxorubicin ToxicityBasic & Clinical Pharmacology & Toxicology, 2005